Cortexyme (CRTX) Peer Comparison
$1.33
$-0.07
(-5.00%)
As on 30-Sep-2022 09:30EDT
Market cap
$70 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Edit
| Cortexyme (CRTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
70 | 17,091 | 14,461 | 12,280 | 12,763 |
Revenue ($ Mln) |
-- | 2,782 | 2,436 | 1,284 | 1,664 |
Net Profit ($ Mln) |
-136.07 | 491.50 | 860.62 | -325.10 | 413.60 |
Net Margin (%) |
-203,091.04 | 17.67 | 35.33 | -25.32 | 24.86 |
RoE (%) |
-129.81 | 110.09 | 42.98 | -57.72 | 430.03 |
Price to Earnings |
-- | 35.98 | 18.35 | -- | 32.13 |
Price-To-Book |
0.66 | 39.58 | 7.84 | 23.60 | 86.73 |
Income Statement ($ Mln)
| Cortexyme (CRTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 1,142.38 | 1,434.97 | 0.00 | 443.31 |
|
Cost of Revenue
|
0.00 | 814.22 | 52.87 | 0.41 | 81.41 |
|
Gross Profit
|
-- | 328.16 | 1,382.10 | 0.00 | 361.90 |
|
Operating Expenses
|
136.06 | 129.54 | 1,095.43 | 242.48 | 86.00 |
|
Operating Profit (EBIT)
|
-69.29 | 198.62 | 286.67 | -242.48 | 275.90 |
|
Other Income
|
0.07 | 3.34 | -0.18 | 0.36 | -19.86 |
|
Profit before Tax
|
-136.36 | 201.85 | 294.15 | -241.85 | 248.52 |
|
Provision for Tax
|
0.00 | 20.00 | 63.09 | -0.77 | -154.19 |
|
Profit after Tax (Net Income)
|
-136.07 | 181.85 | 231.06 | -241.08 | 402.71 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
-52.96 | 181.85 | 231.06 | -241.85 | 402.71 |
Liabilities ($ Mln)
| Cortexyme (CRTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
104.53 | 952.93 | 2,210.62 | 196.11 | 196.95 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.30 | 149.79 | 68.03 | 0.39 | 790.33 |
|
Current Liabilities
|
4.95 | 557.22 | 337.59 | 76.84 | 117.15 |
|
Total Liabilities
|
133.23 | 1,659.94 | 2,616.24 | 273.33 | 1,104.43 |
Assets ($ Mln)
| Cortexyme (CRTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.38 | 969.02 | 781.49 | 1.65 | 178.14 |
|
Current Assets
|
98.28 | 690.91 | 1,834.75 | 271.68 | 926.29 |
|
Total Assets
|
133.23 | 1,659.94 | 2,616.24 | 273.33 | 1,104.43 |
|
Total Debt*
|
0.00 | 130.97 | 51.27 | 0.80 | 876.67 |
|
Net Current Assets
|
0.00 | 133.70 | 1,497.16 | 194.85 | 809.14 |
Cashflow ($ Mln)
| Cortexyme (CRTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-62.93 | 263.33 | 400.80 | -183.92 | 299.44 |
|
Cash Flow from Investing Activities
|
58.95 | -31.36 | -42.88 | -5.06 | -406.29 |
|
Cash from Financing Activities
|
6.81 | -44.45 | -14.80 | 171.24 | 77.87 |
|
Net Cash Inflow / Outflow
|
2.83 | 187.51 | 52.64 | -17.74 | -28.98 |
Ratios
Profitability Ratios
| Cortexyme (CRTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-61.81 | 18.14 | 11.03 | -110.17 | 49.66 |
|
ROE (%)
|
-129.81 | 20.68 | 11.30 | -110.57 | 231.44 |
|
ROA (%)
|
-73.63 | 11.92 | 9.72 | -86.05 | 47.82 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-203,091.04 | 15.87 | 16.10 | -66,412.67 | 95.10 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Cortexyme (CRTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.23 | 0.45 | -- | 0.66 |
|
EBIT Growth (%)
|
-40.34 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-56.22 | 25.08 | 106.71 | -22.10 | 211.97 |
|
EPS Growth (%)
|
-- | 0.25 | 1.04 | -0.11 | 2.14 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Cortexyme (CRTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 45.17 | 25.57 | -6.00 | 14.40 |
|
Price / Book Value
|
-- | 8.62 | 2.67 | 7.38 | 29.45 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
1.19 | 35.34 | 14.96 | -4.86 | 21.28 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Cortexyme (CRTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.14 | 0.02 | 0.00 | 4.45 |
|
Short term debt to equity ratio
|
0.00 | 0.17 | 0.00 | 0.00 | 0.45 |
|
Current Ratio
|
19.87 | 1.24 | 5.43 | 3.54 | 7.91 |
|
Quick Ratio
|
19.87 | -- | 5.35 | -- | 7.45 |
|
Interest Coverage
|
-1,892.82 | 1,923.40 | -- | -232.93 | 36.66 |
Operating Efficiency Ratios
| Cortexyme (CRTX) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 16.32 | 19.70 | -- | 20.52 |
|
Asset Turnover
|
0.00 | 0.75 | 0.60 | 0.00 | 0.53 |
|
Receivable days
|
-- | 55.54 | 56.45 | -- | 77.74 |
|
Inventory Days
|
-- | 0.00 | 167.40 | -- | 257.19 |
|
Payable days
|
-- | 11.71 | 165.41 | 10,099.39 | 7.78 |
|
Cash Conversion Cycle
|
-- | 48.64 | 58.44 | -- | 327.15 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
